Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol M-P, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica [Internet]. 2012Jan.31 [cited 2026Nov.4];97(2):213-8. Available from: https://haematologica.org/article/view/6209